<DOC>
	<DOCNO>NCT00583791</DOCNO>
	<brief_summary>The objective feasibility study investigate safety AMPLATZER Muscular VSD Occluder treatment muscular ventricular septal defect , hemodynamically significant either isolated conjunction congenital heart defect infant child .</brief_summary>
	<brief_title>Closure Muscular Ventricular Septal Defects With The AMPLATZERÂ® Muscular VSD Occluder</brief_title>
	<detailed_description />
	<criteria>Patients hemodynamically significant muscular VSD 's ( demonstrate echocardiography angiography ) , either isolated conjunction congenital heart defect Age &lt; 18 year old Less 4 mm distance semilunar ( aortic pulmonary ) atrioventricular valve ( mitral tricuspid ) Patients severely increased pulmonary vascular resistance 7 wood unit righttoleft shunt document irreversible pulmonary vascular disease Patients perimembranous ( close aortic valve ) VSD Patients &lt; 3 kg Patients sepsis ( local/generalized ) Patients gastritis , gastric ulcer , duodenal ulcer , bleed disorder etc . contraindication aspirin therapy unless antiplatelet agent administer 6 month Inability obtain informed consent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>muscular</keyword>
	<keyword>ventricular</keyword>
	<keyword>septal</keyword>
	<keyword>defect</keyword>
	<keyword>VSD</keyword>
</DOC>